Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
69.76%
Operating Margin
19.18%
Net Margin
12.66%
Efficiency Metrics
Revenue per Expense Ratio
1.24
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
32.00%
Income Tax Rate
26.23%
EPS
3.7300000000
Balance Sheet Analysis
Current Ratio
0.60
Cash Ratio
0.15
Working Capital
$-16.21B
Debt to Equity
1.17
Debt to Assets
36.66%
Equity Ratio
31.23%
Cash Flow Analysis
Operating Cash Flow Ratio
23.44%
Free Cash Flow Ratio
10.66%
CapEx to Revenue
12.78%
Dividends Paid
$4.77B
Stock Buybacks
$11.29B
Total Shareholder Returns
$16.06B
Cash Position Change
31.37%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 7.45%
Detailed Growth Metrics
Core Performance
Revenue
0.12%
Net Income
186.55%
EPS
205.74%
Operating Income
5.57%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
454.44%
Operating Cash Flow
7.91%
Free Cash Flow
2.49%
Balance Sheet Health
Assets
2.93%
Debt
2.40%
Book Value per Share
8.75%
Inventory
0.00%
Shareholder Returns
Dividends per Share
7.45%
Shares Outstanding
-6.45%
Long Term Trends
3Y Revenue/Share
30.26%
5Y Revenue/Share
41.24%
3Y Dividend/Share
27.74%
5Y Dividend/Share
56.12%